

Pamela B Davis, M.D., Ph.D.

office: 216-844-4370

fax: 216-844-4223

email: pamela.davis@case.edu

Education:

Degrees:

A.B. Chemistry, summa cum laude, 1968
Smith College, Northampton, Massachusetts
Ph.D. Physiology and Pharmacology, 1973
Duke University, Durham, North Carolina
M.D. Duke University School of Medicine, 1974
Durham, North Carolina

Internship:

1973-74 Internal Medicine
Duke Hospital

Residency:

1974-75 Internal Medicine
Duke Hospital

Fellowship:

1975-77 Pulmonary Diseases
National Institutes of Health, Bethesda, MD

Academic Appointments:

2003- Senior Associate Dean for Research, Case Western Reserve University School of Medicine
2002- Arline H. and Curtis F. Garvin, M.D., Research Professor, Case Western Reserve University
2002- Professor of Pediatrics, Physiology & Biophysics, and Molecular Biology &
Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH
1991- 2002 Professor of Pediatrics, Medicine, Physiology & Biophysics, and Molecular Biology &
Microbiology, Case Western Reserve University School of Medicine, Cleveland, OH
1994-96 Vice-Chair for Research, Department of Pediatrics
1990-91 Professor of Pediatrics and Medicine
1989-90 Professor of Pediatrics
1985-89 Associate Professor of Pediatrics and Medicine
1984-85 Associate Professor of Medicine and Pediatrics
1983-84 Assistant Professor of Medicine and Pediatrics
1981-83 Assistant Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, Ohio
1979-81 Assistant Professor of Medicine
University of Tennessee College of Medicine
Memphis, Tennessee
1975-79 Clinical Associate/Senior Investigator
Pediatric Metabolism Branch, NIAMDD, NIH, Bethesda, Maryland

Hospital Appointments:

1985- Chief, Pediatric Pulmonary Division
Rainbow Babies and Children's Hospital
1983- Medical staff Physician
University Hospitals Cleveland, Ohio
1982-84 Research Associate, Research Service

Veterans Administration Medical Center, Cleveland, Ohio
 1981-82; Staff Physician, Medical Service
 1985 Veterans Administration Medical Center Cleveland, Ohio
 Graduate School Appointments:
 1991- Biochemistry Faculty
 Molecular Biology and Microbiology Faculty
 Physiology and Biophysics Faculty
 Pharmacology Faculty

Military Service:
 1975-79 U.S. Public Health Service

Certification:
 Diplomate, National Board of Medicine Examiners 1974
 American Board of Internal Medicine (certificate 54013) 1976
 Pulmonary Disease 1980
 American Board of Pediatrics 1996 (recertified 2003 through 2010)
 Pediatric Pulmonology 2000

Licensed US independent user of radionuclides by AEC 1975
 State of Ohio License (#46101) 1981

Drug Enforcement Administration (AD1174832) 1975

Honors and Awards
 A.B. granted summa cum laude, Smith College 1968
 American Chemical Society Prize, Frances Hause Memorial Prize,
 Chemistry, Smith College 1968
 Phi Beta Kappa 1968
 Sigma Xi 1968
 Alpha Omega Alpha 1970
 National Institute of Health, MSTP Training Grant 1968-73
 Named in Who's Who in America (also subdirectories) ~1991- present
 Named in "Best Doctors in America" (also regional subdirectories) 1996, 98, 2002, 2003
 Named in America's Top Doctors 2000-2003
 NE Ohio Top Docs 2000-2004

Samuel Rosenthal Prize for Academic Pediatrics 1996
 Maurice Saltzman Award from the Mt. Sinai Health Foundation,
 Cleveland OH 1998

Smith College Medal 2001

Cleveland Medical Hall of Fame 2001
 Named in "Guide to America's Top Pediatricians" 2002
 Northern Ohio Live Top Rainmaker in Education and Research 2002
 Arline H. and Curtis F. Garvin Research Professorship 2002-

Membership in Professional Societies
 Society for Pediatric Research
 Fellow, American College of Physicians
 American Thoracic Society
 American Federation for Clinical Research, 1980, Southern Regional Councilor, 1981
 National Councilor, 1983-88
 Public Policy Committee, 1983-90 Chairman, 1986-88
 Awards Committee, 1985-90
 Program Committee, 1985-90
 President-Elect 1988-89

President, 1989-90
 American Physiological Society
 American Pediatric Society
 American Academy of Pediatrics
 American Society for Gene Therapy
 Biophysical Society

Professional Service

National

Cystic Fibrosis Foundation (National):
 Conferences Subcommittee, 1978-1980
 Young Adult/Consumer Services Committee, 1978-82 (Vice-Chairman, 1980-1982)
 Research Committee, 1982-86 (Vice-Chairman, 1982-1983, Chairman, 1984-1986)
 Clinical Research Committee, 1983-86 (Chairman, 1983-1986)
 Review Group, Therapeutics Development Grants 1998 (chair)
 Medical Advisory Council, 1983-92 (Vice Chairman, 1986-88, Chairman, 1988-90)
 Board of Trustees, 1986-90 (Finance Committee, 1986-88 Executive Committee, 1988-90)
 Organizing Committee, N. American CF Conference, 1990, 1997-2003; Chair, 1997 Conference

American Thoracic Society
 Scientific Advisory Council, 1989-93, 1994-95
 Ad hoc Committee on Asthma Centers, 1991
 Planning Committee, Asthma Workshop, 1993
 Long-range planning committee, 1994-97
 Training and Manpower Committee 1997

Research!America, Board of Directors, 1989-90

Outside Advisory Committee, Columbia University Cystic Fibrosis Research Center, 1989-93; CF Research Center, Mayo Clinic Scottsdale AZ (J. Riordan, P.I.) 1995; CF Research Center, U of Alabama, Birmingham AL (E. Sorscher, P.I.) 1995- 00; CF Research Center, U of Colorado Consortium, Denver CO. (F.Accurso, P.I.) 1996; University of Pittsburgh CF Research Development Center (R. Frizzell, P.I.) 1998- ; University of Cincinnati CF Research Development Center (J. Whitsett, P.I.) 1999

National Institutes of Health: Search Committee, NIDDK Associate Director, 1991
 National Advisory Council, NIDDK, 1992-96
 Member, Panel to Assess the NIH Investment in Research on Gene Therapy 1995
 Special Emphasis Panel, NHLBI, Genetic testing in epidemiologic research 1996-97
 NIH Director's Panel to Evaluate the performance of the Director, NIDDK, 1997
 Working group for the Biochemical Sciences, NIH Center for Scientific Review, 2000-1
 Data and safety monitoring board for NHLBI Gene Therapy Centers, 2001-
 Consultant, National Gene Vector Laboratory (nonviral vectors): Scientific Review Board. Des Moines, Iowa 2000-
 Board of Scientific Counselors, NHLBI, 2001-2006, Chair 2004-
 Session Chair, Becon Symposium on Catalyzing Team Science NIBIB Sept 2003

Data Safety Monitoring Board, DNAase Study, Genentech, Chairman, 1991
 Society for Pediatric Research, Abstract reviewer and pulmonary session chairman, 1991-92
 Allen & Hanbury's Fellowship Advisory Committee, 1991-94
 Burroughs Wellcome Fund, Advisory Committee for Experimental Therapeutics, 1992-97 Chair, 1995-97;
 Advisory Committee for Translational Research, Chair, 1997-99 ; ad hoc reviews, 2000-
 Safety monitor, DuPont Merck study of DMP 777 in cystic fibrosis patients 1997-00
 Consultant, Targeted Genetics, Inc. Seattle WA 1997-98
 American Society for Gene Therapy, Public Policy Committee, 1997- 01
 Abstract reviews 2000, 2001, 2002 (chair, molecular conjugates subgroup 2001, 2002) Non viral group

2004-
 Scientific founder and Scientific Advisory Board, Copernicus Gene Systems, 1997-
 Scientific Advisory Board, Arizeke Pharmaceuticals, 2003-

Community

Cystic Fibrosis Foundation, Rainbow Chapter, Medical Advisory Board, 1981-1987
 Chairman, 1989
 Board of Directors, 1996-99, 2002-03

Medicine and Health Co-Chair, Judges, Intel International Science and Engineering Fair, May 2003, Cleveland OH

University

University of Tennessee College of Medicine

Assistant Director for Outpatient Services, Clinical Research Center, 1980-81

Case Western Reserve University

Research Committee, 1989-92, Chairman, 1991-92

Search Committee, Vice-President for Research, 1996-97

Ad Hoc Faculty Partnership Committee for the CWRU-UH Academic Health Center 2002

Commission on Research and Graduate Programs, 2002-03

Ad hoc group to reengineer research infrastructure 2003

Provost's Research Council 2004-

Case Western Reserve University School of Medicine

Search Committee for Chairman of Nutrition Department, 1984-85

Research and Development Committee, V.A.M.C., 1985

Search Committee for Chairman, Department of Medicine, 1985-86

Research Committee, 1986- , Chair, 1990-92, 2001-

Medical Scientist Training Program Steering Committee, 1986-90

Task Force on Research Development, Cardiorespiratory/Renal Focus, Chairman 1990

Lecture Committee, 1993-96, Chairman, 1993-96

GCRC Dean's Advisory Council 1994-97

GCRC Scientific Advisory Committee 1994-97

Search Committee for Dean, School of Medicine, 1995

Biomedical Research Cleveland Working Group, 1995-00

Howard Hughes Program Steering Committee, 1996-00, Search Committee for ion transport, 1996-00

Ad hoc Committee to assess admissions policies for the School of Medicine, 1996

Steering Committee, Gene Therapy Facility 1997-03

Search Committee for Chair, Department of Biochemistry, 1997-98

Research Planning Committee, School of Medicine, Co-Chair 1997-99

Executive Committee, School of Medicine, 1998- 03

Committee on Technology Transfer, School of Medicine, 1998-00

Search Committee, Chair of Molecular Biology and Microbiology, 1999-2001

Search Committee, Head of Technology Transfer, School of Medicine, 1999

Search Committee, Director of Veterinary Research Resources, chair, 1999-2000

Committee on Qualifications and Standards for Promotion (ad hoc), CWRU SOM 1999

Search Committee, Chair of Anatomy and Cell Biology, 2000

Advisory Committee, GCRC training for physician-scientists, 2000-

Dean's Advisory Committee on Women's Professional Activities, 2000-02

Search Committee, Vice Dean for Research, School of Medicine, chair, 2001-2

Steering Committee, LCME reaccreditation of the SOM, 2001-2

Acting Dean's Advisory Group, 2002- 3

Dean's Operating Committee 2003-

Search Committee, Chair of Pharmacology, 2003-

University Hospitals of Cleveland

Rainbow Babies and Children's Hospital Planning and Priorities Committee, 1985-89

Co-Medical Director, Pediatric Respiratory Therapy, 1985-98

Strategic Planning Group, Cardiopulmonary Task Force, Chairman, 1988

Director, Pediatric Endoscopy Unit, 1986-88

Director, Pediatric Pulmonary Home Care Program, 1987-93

Credentialing Committee, Pediatrics, 1986-90

Co-Director, Pediatric Pulmonary Function Lab, 1991-98

Member, Cardiopulmonary Task Force, Rainbow 2000 Strategic Planning Exercise, 1992-93

Pharmacology and Therapeutics Committee

Drug Evaluation Subcommittee, 1992-93

Rainbow Babies and Childrens Hospital Board of Trustees, Allocations Board, 1993-98

Rainbow 2000 Implementation Committee, 1994
 Rainbow Media Relations Committee, 1996-99
 Residency Training Director, Medicine-Pediatrics Residency 1997-2000
 Planning Committee, University Hospitals Research Institute Building 1999-2000
 Research and Education subcommittee, Strategic Planning Process, UHC 2004.

Department of Pediatrics, Case Western Reserve University

Academic Planning Committee, 1985-
 Research Committee, 1986-90, 1991-92, 1994- (Chairman, 1994-1996)
 Committee on Appointments, Promotions, and Tenure, 1986-90
 Internal Review Committee (Chairman), 1987-88
 Chairman, Task Force on Faculty Compensation, 1990, 1992
 Finance Committee, 1992-96; 1999- Chairman, 1993-95
 Vice-President, Children's Research Foundation (dept practice plan/foundation: elected position) 1994-

96

Search Committee for Vice Chair for Research, Chair, 1999

Department of Physiology & Biophysics, Case Western Reserve University

Ph.D. for M.D.'s Admissions Committee, 1991-93
 Seminar Committee, 1992
 Appointments, Promotions, and Tenure Committee, 1993- , Chairman, 1993-99
 Steering Committee, 1993-96, 2002-
 Committee to revise the administrative structure, 1999

Department of Molecular Biology and Microbiology, Case Western Reserve University

Ad hoc Committee on Appointments, Promotions, and Tenure, 2000, 2002

Editorial Boards:

American Journal of Respiratory Cell and Molecular Biology (Associate Editor, 2001-)
 Respiratory Research (Associate Editor, 2000-)

Reviewer for (Journals):

American Journal of Physiology
 American Review of Respiratory Diseases/ American Journal of Respiratory and Critical Care Medicine
 American Journal of Respiratory Cell and Molecular Biology
 Human Molecular Genetics
 Journal of Applied Physiology: Respiratory, Environmental, Exercise Physiology
 Journal of Biological Chemistry
 Journal of Clinical Investigation
 Journal of Pediatrics
 Nature, Nature Medicine, Nature Genetics, Nature Biotechnology
 New England Journal of Medicine
 Pediatric Pulmonology
 Pediatric Research
 Gene Therapy
 Biochemical Pharmacology
 Lung
 Biochem Biophys Acta

Reviewer for (Granting Agencies):

Cystic Fibrosis Foundation (National) Research Committee (reviews regular laboratory research grants and fellowships, Chairman 1984-86), Research Resources Development Program (ad hoc reviewer), Clinical Research Committee (Chairman 1983-86); Therapeutic Development Centers Review Committee (Chair, 1997-) ad hoc- (1995- present, various offerings)
 Cystic Fibrosis Foundation (Rainbow Chapter, Northeast Ohio)
 Study section member 1981-87, Chairman 1989
 Thrasher Foundation (ad hoc)
 Veteran's Administration (ad hoc)
 NIH/NIAMDD/NIDDK/NHLBI Ad hoc Program Project and Core Center site visits and reviews; various study

sections, ad hoc 1985-present
 NIDDK Subcommittee B 1987-1991
 Review of program projects, K series, T and F series grants, and advice to the director. Chairman, 1989-1991
 Chairman, ad hoc study section to review P50 grant submissions in Cystic Fibrosis, NIDDK-NHLBI
 July 1988, April 1989 (10 P50 grant reviews)
 Chairman, special review group to review PO1 submissions on Gene Therapy, NHLBI
 July 1993 (6 PO1 grant reviews). Member of panel to review renewals, 1998.
 Medical Research Council (Canada) IHRT applications, 2000
 Board of Scientific Counselors, National Heart, Lung, and Blood Institute, 2001-2006 , Chair, 2004-2006

Teaching Experience

Jan-Feb 1980, 1981	Attending Physician, City of Memphis Hospital, inpatient service and outpatient clinic (University of Tennessee Medical Service)
March-June 1980	
Sept-Dec 1980	Preceptor, Physical Diagnosis Course, University of Tennessee College of Medicine
Sept 1981-July 1985 (11 months)	Attending Physician, Medical Services, VAMC, Cleveland, OH
July-Oct 1981	Preceptor, Medical Referral Clinic, VAMC, Cleveland, Ohio
Sept-Dec 1981	Preceptor, Physical Diagnosis Course, CWRU
1982-85, 87-89	Phase II Respiratory Committee lectures
1982, 1983	Lecturer and Small group leader, Phase I Fundamentals of Therapeutic Agents Section
Feb 1984, 85	Phase I Pulmonary Section, lecture
1985-1989, 1992-93 (1-2 mos/year)	Attending Physician, General Pediatrics Rainbow Babies and Childrens Hospital (modified sabbatical, 1990-91)
1986-1989, 1992-present (~1 mo/year)	Pulmonary Inpatient and Consult Service, Rainbow Babies and Childrens Hospital (modified sabbatical 1990-91)
July 1986	Organizer and Preceptor, Pediatric Fellows Introductory Course
July 1986-92	Lecturer, Pediatric Fellows Introductory Course
1994-present	Lecturer, Pediatric Pulmonology Fellows Course
Spring 1993-02	Physical Diagnosis, small groups (Pediatrics)
Fall 1993	Graduate Course, M BIO 451, Molecular Biology of Proteins Important in Health and Disease
Spring 1994-2000, Fall 2002	Lecturer, Membrane Biology Course, PHOL 472 Department of Physiology and Biophysics
Summer 1994	Preceptor, LEAP Summer program (Teaching award)
Summer 1994-1998	Lecturer, Summer SPUR program through Dept of Physiology & Biophysics

Fall 1997- pres Clinical correlation lectures/small groups to first and second year med students - CF (University program and 2004- Cleveland Clinic Lerner College of Medicine)

Summers 1995- pres Summer students laboratory experiences, supervisor

Fellows Supervised

1980-81, 1984-86 Elizabeth Rich, M.D. (Adult Pulmonology, Associate Professor of Medicine, CWRU, deceased 1998)

1985-88 Michael Konstan, M.D., (Pediatric Pulmonology, Associate Professor of Pediatrics, CWRU, and Director, Leroy Matthews Cystic Fibrosis Center, CWRU)

1987-88 Robert Cohn, M.D. (Pediatric Pulmonology, now Chair, Department of Pediatrics and Associate Professor of Pediatrics, CWRU, MetroHealth Medical Center)

1987-89 Michael Infeld, M.D. (Adult Pulmonology, Associate Professor of Pediatrics and Medicine, CWRU and Director, Adult Program, Leroy Matthews Cystic Fibrosis Center, CWRU).

1987-90 Youngran Chung, M.D. (Pediatric Pulmonology, now Assistant Clinical Professor of Pediatrics, University of Illinois, Chicago, IL)

1987-90 Michael Fiedler, M.D. (Pediatric Pulmonology, Assistant Clinical Professor of Pediatrics, University of Cincinnati)

1988-91 David Birnkrant, M.D. (Pediatric Pulmonology, Associate Professor of Pediatrics, CWRU, MetroHealth Medical Center)

1988-92 John Carl, M.D. (Pediatric Pulmonology, Associate Prof. of Pediatrics, CWRU)

1990-95 Aura Perez, Ph.D. (Physiology, now Instructor of Pediatrics, CWRU)

1992-96 Dianne Kube, Ph.D. (Mol Biology, Supervisor, Videomicroscopy Facility, CWRU)

1992-95 Girish Sharma, M.D. (Pediatric Pulmonology, Assistant Professor of Pediatrics, CF Center Director, and Section Head, Pediatric Pulmonology, Rush University, Chicago, IL)

1994-96 Karen McDowell, M.D. (Pediatric Pulmonology, now Head of Pediatric Pulmonology, Cleveland Clinic Foundation)

1996-2001 Junxia Xie, Ph.D. (Physiology & Biophysics, now Assistant Professor of Molecular and Cellular Biology, Robert Wood Johnson Medical School, New Jersey)

1998- 2003 Sanhita Gupta, Ph.D. (Molecular Biology, now 6/03 Head of Microbiology Division, Public Health Scientist, New Orleans, LA)

1999- 2003 Assem Ziady, Ph.D. (Physiology & Biophysics) (now Asst Prof of Pediatrics, CWRU)

2003- Daniel Hsu, M.D. (Pediatric Pulmonology)

Graduate Committees (not thesis adviser)

Paul Hmiel, Ph.D. 1988, Pharmacology (MSTP student)

Samuel DelRio, Microbiology and Molecular Biology Ph.D. 1992 (MSTP student)

Michael Grant, Pharmacology Ph.D. 1991 (MSTP student)

Christopher Vincent, Physiology and Biophysics Ph.D. 1993 (Ph.D. for MD's program)

Stacey Piszczkiewicz Memberg, Neurosciences (MSTP student), Ph.D. 1995

Erin Clifford, Physiology & Biophysics (M.D.-Ph.D. student) Ph.D. 1998

Bryan Zerheusen, Physiology & Biophysics Ph.D. 2000

Rohit Kashyap, Biomedical Engineering Ph.D. 1999

Rebecca Marsick, Genetic Counseling, M.S. 2000

Min Yan, Molecular Biology, 2001-

Lewis Rosenberg, Genetics, 2002 -

Damon Sutton, Macromolecular Sciences, 2003 -

Graduate Students Supervised (thesis adviser)

Rohit Kashyap, Biomedical Engineering, M.S. 1992-94

Jason Tasch, Molecular Biology and Microbiology, 1993-1999 Ph.D. 2000

Elizabeth Eckman, Molecular Biology and Microbiology, 1993-98, Ph.D., 1998 (now Asst Prof, Mayo Clinic, Jacksonville FL)

Junxia Xie, Physiology and Biophysics, 1994-1996. Ph.D., 1996 (now Res Asst Prof, Robert Wood Johnson Medical School, Piscataway NJ)

Claudia Ute Kreibig, Physiology and Biophysics, 1994-97 (M.S. 1997)

Assem Ziady, Physiology and Biophysics, 1995-98, Ph.D., 1999 (now Asst Prof, CWRU SOM, Cleveland OH)

Lynn Adams, Physiology and Biophysics, 1998-99 (M.S. 1999)

Melanie Funke, Biochemistry 2000-
Timothy Miller, Molecular Pharmacology, 2001-

PUBLICATIONS

Papers

1. Davis, P.B. Studies on DNA polymerase in regenerating rat liver. Doctoral Dissertation, Duke University, 1973.
2. Davis, P.B., Laszlo, J. and Baril, E.F. Induction of DNA polymerase during liver regeneration in rats on controlled feeding schedules. *Cancer Res.* 36:432-437, 1976.
3. di Sant'Agnese, P.A. and Davis, P.B. Research in cystic fibrosis. *N. Engl. J. Med.* 295:481-485, 534-541, and 597-602, 1976.
4. Davis, P.B., Braunstein, M. and Jay, C. Decreased adenosine 3':5' cyclic monophosphate response to isoproterenol in cystic fibrosis leukocytes. *Pediatr. Res.* 12:703-707, 1978.
5. Davis, P.B. and di Sant'Agnese, P.A. Assisted ventilation for patients with cystic fibrosis. *J. Am. Med. Assn.* 239:1851-1854, 1978.
6. Davis, P.B. Urinary cyclic nucleotides in adult male cystic fibrosis patients. *Clin. Chim. Acta* 87:285-288, 1978.
7. di Sant'Agnese, P.A. and Davis, P.B. Adults with cystic fibrosis: 75 cases and a review of 232 cases in the literature. *Am. J. Med.* 66:121-132, 1979.
8. Lake, C.R., Davis, P.B., Ziegler, M. and Kopin, I. Electrolytes and norepinephrine levels in blood of patients with cystic fibrosis. *Clin. Chim. Acta* 92:141-146, 1979.
9. Hubbard, V.S., Davis, P.B., Schwartz, R., Gorden, P. and di Sant'Agnese, P.A. Isolated growth hormone deficiency and cystic fibrosis. *Am. J. Dis. Childh.* 134:317-319, 1980.
10. Hubbard, V.S., Davis, P.B. and di Sant'Agnese, P.A. Possible hazard of timed-release aspirin in a patient with pancreatic insufficiency. *Arch. Int. Med.* 139:1054-1055, 1979.
11. di Sant'Agnese, P.A. and Davis, P.B. Recent research in cystic fibrosis. *Monogr. Paed.* 10:66-76, 1979.
12. Davis, P.B., Hill, S.C. and Ulane, M.M. Hormone stimulated cyclic AMP production by skin fibroblasts cultured from healthy persons and patients with cystic fibrosis. *Pediatr. Res.* 14:863-868, 1980.
13. Davis, P.B., Hubbard, V.S. and di Sant'Agnese, P.A. Low sweat electrolytes in a patient with cystic fibrosis. *Am. J. Med.* 69:643-646, 1980.
14. Davis, P.B., Shelhamer, J. and Kaliner, M. Abnormal adrenergic and cholinergic sensitivity in cystic fibrosis. *N. Engl. J. Med.* 302:1453-1456, 1980.
15. Davis, P.B. and Hill, S.C. Adenylate cyclase activity in leukocytes from patients with cystic fibrosis. *J. Lab. Clin. Med.* 96:75-85, 1980.
16. Davis, P.B. and di Sant'Agnese, P.A. CF at Forty - Quo Vadis? *Pediatr. Res.* 14:83-87, 1980.
17. Davis, P.B. and Lieberman, P. Normal alpha₂-adrenergic responses in platelets from subjects with asthma. *J. Allergy Clin. Immunol.* 69:35-38, 1982.
18. Kaliner, M., Shelhamer, J., Smith, L., Davis, P.B. and Venter, J.C. NIH Conference. Autonomic nervous system abnormalities and allergy. *Ann. Intern. Med.* 96:349-357, 1982.

19. Davis, P.B. and Kaliner, M. Autonomic nervous system abnormalities in cystic fibrosis. *J. Chr. Disease* 36: 269-278, 1983.
20. Davis, P.B., Hubbard, V.S., Taussig, L.M., and McCoy, K. Medical progress: Familial bronchiectasis. *J. Pediatrics* 102:177-185, 1983.
21. Davis, P.B. Cystic fibrosis. *Clin. Notes Respir. Dis.* 21:3-12, 1983.
22. Davis, P.B., del Rio, S., Muntz, J. and Dieckman, L. Sweat chloride concentrations in adults with pulmonary diseases. *Am. Rev. Respir. Dis.* 128:34-37, 1983.
23. Davis, P.B., Dieckman, L., Boat, T.F., Stern, R.C. and Doershuk, C.F. Beta- adrenergic receptors on lymphocytes and granulocytes from patients with cystic fibrosis. *J. Clin. Invest.* 71:1787-1795, 1983.
24. Davis, P.B., Dieckman, L., Boat, T.F., Stern, R.C. and Doershuk, C.F. The α_2 - adrenergic system of the platelet in cystic fibrosis. *Am. J. Med. Sci.* 288:104-108, 1984.
25. Davis, P.B., Hubbard, V.S., Dieckman, L., Boat, T.F., Stern, R.C. and Doershuk, C.F. Effects of α -tocopherol on platelet membrane function on cystic fibrosis. *J. Lab. Clin. Med.* 104:203-212, 1984.
26. Davis, P.B. Autonomic and airway reactivity in obligate heterozygotes for cystic fibrosis. *Am. Rev. Respir. Dis.* 129:911-914, 1984.
27. Davis, P.B., di Sant'Agnese, P.A. Diagnosis and treatment of cystic fibrosis: An update. *Chest* 85:802-809, 1984.
28. Davis, P.B. Pathogenesis of Pulmonary Disease in CF. *Sem. Respir. Med.* 6:261-270, 1985.
29. Davis, P.B., Paget, G.L. and Turi, V. Alpha-adrenergic responses in asthma: In vivo and in vitro. *J. Lab. Clin. Med.* 105:164-169, 1985.
30. Davis, P.B. Reproductive Complications of CF. *Sem. Respir. Med.* 6:314-318, 1985.
31. Davis, P.B. Miscellaneous Complications of CF. *Sem. Respir. Med.* 6:319-320, 1985.
32. Davis, P.B., Hubbard, V.S. and Garvin, A.J. Bronchiectasis and oligospermia: Report of two families. *Thorax* 40:376-379, 1985.
33. Davis, P.B. Pupillary responses and airway reactivity in asthma. *J. Allergy Clin. Immunol.* 77:667-672, 1986.
34. Davis, P.B., Simpson, D.M., Paget, G.L. and Turi, V. Beta-adrenergic responses in drug-free asthmatic subjects. *J. Allergy Clin. Immunol.* 77:871-879, 1986.
35. Davis, P.B. Lymphocyte and granulocyte phosphatidylethanolamine N-methyl transferase: properties and activity in cystic fibrosis. *Pediat. Res.*, 20:1290-1296, 1986.
36. Davis, P.B. Physiologic implications of autonomic aberrations in cystic fibrosis. *Hormone Metab. Res.* 18: 217-220, 1986.
37. Davis, P.B. Pathophysiology of cystic fibrosis: with emphasis on salivary gland involvement. *J. Dent. Res.*, 66:667-671, 1987.
38. Davis, P.B. and Vargo, K. Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis. *Thorax*, 42: 120-125, 1987.
39. Davis, P.B. and Silski, C. The α_2 -adrenergic system in the platelet; changes with aging. *Clinical Science*, 78:507-513, 1987.
40. Davis, P.B. and Byard, P. Relationships among airway reactivity, pupillary alpha- adrenergic and cholinergic responsiveness and age in healthy subjects. *J. Appl. Physiol.* 65:200-204, 1988.

41. Byard, P. and Davis, P.B. Pulmonary function in obligate heterozygotes for cystic fibrosis. *Am. Rev. Respir. Dis.* 138:312-316, 1988.
42. Davis P.B. and Byard, P.J. Heterozygotes for cystic fibrosis: Models for study of airway and autonomic reactivity. *J. Appl. Physiol.* 66:2124-2128, 1989.
43. Lewin, L., Byard, P. and Davis, P.B. Effect of *Pseudomonas cepacia* colonization on survival and pulmonary function of cystic fibrosis patients. *J. Clin Epidemiol.* 43:125-131, 1990.
44. Mader, S.L. and Davis, P.B. Effect of age on acute regulation of beta-adrenergic responses in mononuclear leukocytes. *J. Gerontol.* 44:M168-173, 1989.
45. Konstan, M.W., Vargo, K. and Davis, P.B. Ibuprofen attenuates inflammation in a model of chronic pulmonary infection. *Am. Rev. Resp. Dis.* 141:186-192, 1990.
46. Davis, P.B., Silski, C., Kercksmar, C. and Infeld, M. Beta-adrenergic receptors on human tracheal epithelial cells in primary culture. *Am. J. Physiol: Cell Physiol.* 258(27):C71-C76, 1990.
47. Kercksmar, C.M., Silski, C., Infeld, M. and Davis, P. Adenosine 3':5' cyclic monophosphate synthesis by human tracheal epithelial cells. *Am. J. Resp. Cell. Mol. Biol.* 2:33-39, 1990.
48. Davis, P.B. and Byard, P. Beta-adrenergic responses and airway reactivity in healthy adults. *Mech Ageing and Dev.* 54:29-42, 1990.
49. Davis, P.B. Public Policy in the AFRCR: The First Fifty Years. AFRCR Presidential Address. *Clin. Res.* 38:529-536, 1990.
50. Davis, P.B. Conference Summary: Cystic Fibrosis, Cell and Molecular Biology. *J. Appl. Physiol.* 70:2331-2333, 1991.
51. Konstan, M, Hoppel, C.L., Chai, B. and Davis, P.B. Ibuprofen in children with cystic fibrosis: Pharmacokinetics and adverse effects. *J. Pediatr.* 118:956-964, 1991.
52. Fiedler, M.A., Kaetzel, C.S., and Davis, P.B. Sustained production of secretory component, the polymeric IgA receptor, by human tracheal epithelial cells in primary culture. *Am. J. Physiol: Lung Cell Mol. Physiol.* 5: L255-L261, 1991.
53. Stark, J., Huang, Y., Carl, J. and Davis, P.B. Infection of cultured human tracheal epithelial cells by human parainfluenza virus types 2 and 3. *J. Virol. Meth.* 31:31-46, 1991.
54. Chung, Y., Kercksmar, C. and Davis, P.B. Ferret tracheal epithelial cells grown in vitro are resistant to lethal injury by activated neutrophils. *Am J Resp Cell Mol Biol* 5:125-132, 1991.
55. Kercksmar, C.M., Chung, Y. and Davis, P.B. Receptor-mediated cAMP production in adult and infant ferret tracheal epithelium. *Pediatr Res* 30:75-82, 1991.
56. Birnkrant, D., Mader, S.L., vanLunteren, E., and Davis, P.B. Chronic hypoxia increases β -adrenergic receptor density in the lungs of young and old rats. *Mech Ageing and Dev* 60:135-142, 1991.
57. Davis, P.B. Cystic fibrosis from bench to bedside. *N. Engl. J. Med.* 325:575-577, 1991.
58. Davis, P.B., Silski, C and Liedtke, C.M. Amiloride antagonizes β -adrenergic stimulation of cAMP synthesis and Cl^- secretion in human tracheal epithelial cells. *Am. J. Resp. Cell Mol. Biol.* 6:140-145, 1992.
59. Alpert, S.A., Walenga, R.W., Kramer, C.M., Silski, C.L., and Davis, P.B. Tracheal epithelial cell fatty acid composition modulates eicosanoid and cAMP production. *Am. J. Physiol.* 262: Lung Cell Mol. Physiol. 6: L192-197, 1992.

60. Infeld, M.D., Brennan, J.A., and Davis, P.B. Human tracheobronchial epithelial cells direct migration of human lung fibroblasts within three-dimensional collagen gels. *Am. J. Physiol.* 262 (Lung Cell. Mol. Physiol. 6): L535-L541, 1992.
61. Kercksmar, C.M. and Davis, P.B. Resistance of human tracheal epithelial cells to killing by neutrophils, neutrophil elastase and pseudomonas elastase. *Am. J. Resp. Cell Mol. Biol.* 8:56-62, 1993.
62. Infeld, M.D., Brennan, J.A. and Davis, P.B. Human fetal lung fibroblasts promote invasion of extracellular matrix by normal human tracheobronchial epithelial cells in vitro: a model of early airway gland development. *Am. J. Respir. Cell Mol. Biol.* 8:69-76, 1993.
63. Ferkol, T., Kaetzel, C. and Davis, P.B. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. *J. Clin. Invest.* 92:2394-2400, 1993.
64. Birnkrant, D., Davis, P.B, and Ernsberger, P. Visualization of high- and low-affinity β -adrenergic receptors in rat lung: Up-regulation by chronic hypoxia. *Am. J. Physiol.: Lung Cell. Molec. Physiol.* 265:L389-L394, 1993.
65. Demko, C., Byard, P., Davis, P.B. Gender differences in cystic fibrosis: *Pseudomonas aeruginosa* infection. *J. Clin. Epidemiol.* 48:1041-1050, 1995.
66. Davis, P.B., Perez, A. and Silski, C. cAMP does not regulate $[Ca^{++}]_i$ in human tracheal epithelial cells in primary culture. *J Cell Sci.* 107:2899-2907, 1994.
67. Davis, P.B. Evolution of therapy for cystic fibrosis *New Engl J Med* 331: 672-3, 1994.
68. Sharma, G., Stern, R.C., Tosi, M., Davis, P.B. Progression of pulmonary disease after loss of *Pseudomonas aeruginosa* in cystic fibrosis. *Am J Resp Crit Care Med* 152: 169-173, 1995
69. Ferkol, T.F., Perales, J.C., Kaetzel, C.S., Eckman, E. Hanson, R.W. and Davis, P.B. Gene transfer into the airway epithelium of animals by targeting the polymeric immunoglobulin receptor. *J. Clin Invest.* 95:493-502, 1995.
70. Konstan, M.W., Byard, P.J., Hoppel, C.L., Davis, P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis: results of a four-year randomized double-blind placebo-controlled trial. *New Engl JMed*, 332:848-856, 1995
71. Davis, P.B. Intruder in the dust: Why is dust mite such an effective allergen? *Am J Resp Cell and Mol Biol.* 12: 367-8, 1995.
72. Davis, P.B. Saturday's Children. *Amer. J. Resp. Crit. Care Med.* 152:1-2, 1995.
73. Chetty, A., Infeld, M., Davis, P.B. Effect of human neutrophil elastase on the haptotactic response of fetal lung fibroblasts to human tracheal epithelial cells in vitro. *Exp. Lung Res.* 21:889-899, 1996.
74. Eckman, E., Cotton, C., Kube, D., Davis, P.B. Dietary changes improve survival of the CFTR S489X homozygous mutant mouse. *Am. J. Physiol.* 269: L625-L630, 1995.
75. Xie, J., Drumm, M.L., Ma, J. and Davis, P.B. Intracellular loop between TM4 and TM5 of CFTR is involved in regulation of chloride channel conductance. *J. Biol. Chem.* 270:28084-28091, 1995.
76. Tao, T. Xie, J. Drumm, M.L. Zhao, J. Davis, P. B. and Ma, J. Slow conversions among subconductance states of cystic fibrosis transmembrane conductance regulator chloride channel. *Biophysical J.* 70:743-753, 1996.
77. Ma, J., Tasch, J., Tao, T., Zhao, J., Xie, J., Drumm, M.L., and Davis, P.B. Phosphorylation-dependent block of cystic fibrosis transmembrane conductance regulator chloride channel by exogenous R domain protein. *J. Biol. Chem.* 271:7351-7356, 1996
78. Perez, A., Risma, K.A., Eckman, E.A. and Davis, P.B. Overexpression of R domain reduces basal chloride conductance and eliminates cAMP stimulated chloride secretion in 9/HTEo⁻ cells in culture. *Am. J. Physiol.*

- 271: L85-L92, 1996.
79. Davis, P.B., Drumm, M.L., and Konstan, M.W. State of the Art: Cystic Fibrosis. *Am J. Resp. Crit. Care Med.*, 154: 1229-1256, 1996.
 80. Ferkol, T.W., Pellicena-Palle A., Eckman, E., Perales, J.C., Trzaska, T. Tosi, M., Redline, R. Davis, P.B. Immunologic responses of gene transfer into mice via the polymeric immunoglobulin receptor. *Gene Therapy* 3:669-678, 1996.
 81. Xie, J., Drumm, M.L., Zhao, J. Ma, J. Davis, P.B. Human epithelial CFTR without Exon 5 maintains partial chloride channel function in intracellular membranes. *Biophysical J.* 71:3148-3156, 1996
 82. Zhao, J., Zerhusen, B., Xie, J. Drumm, M.L., Davis, P.B. Ma, J. Rectification of CFTR chloride channels mediated by extracellular divalent cations. *Biophysical J.* 71:2458-2466, 1996.
 8382. Davis, P.B., Byard, P.J., and Konstan, M.W. Identifying treatments which halt progression of pulmonary disease in cystic fibrosis. *Pediatr. Res.* 41:161-165, 1997.
 84. Ziady, A-G., Perales, J., Ferkol, T., Gerken, T. Beegen, H., Perlmutter, D., and Davis, P.B. Gene transfer into hepatoma cell lines via the serpin enzyme complex (SEC) receptor. *Am. J. Physiol.* 273 (Gastrointest. Liver Physiol. 36): G545-G552, 1997.
 85. Davis, P.B. The decline and fall of pulmonary function in cystic fibrosis: new models, new lessons, Editorial, *J. Pediatr.*, 131:789-90, 1997.
 86. Ma, J., Zhao, J., Drumm, M.L., Xie, J., and Davis, P.B. Function of the R domain in the CFTR chloride channel. *J. Biol. Chem.* 272:28133-28141, 1997.
 87. van Heeckeren, A., Walenga, R, Konstan, M.W., Bonfield, T., Davis, P.B., and Ferkol, T. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with *Pseudomonas aeruginosa*. *J. Clin Invest.* 100:2810-2815, 1997.
 88. Bryan, R., Kube, D. Perez, A., Davis, P. and Prince A. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased *Pseudomonas aeruginosa* binding by epithelial cells. *Am. J. Respir. Cell Mol Biol.* 19:269-277, 1998.
 89. Ziady, A. Ferkol, T., Gerken, T., Dawson, D.V., Perlmutter, D.H., Davis, P.B. Ligand substitution of receptor targeted DNA complexes affects gene transfer into hepatoma cells. *Gene Therapy.* 5:1685-1697, 1998.
 90. Ziady, A-G., Ferkol, T., Dawson, D.V., Perlmutter, D.H., and Davis, P.B. Chain length of the polylysine in receptor-targeted gene transfer complexes affects duration of reporter gene expression both in vitro and in vivo. *J. Biol. Chem.* 274:4908-4916, 1999.
 91. Tasch, J. Ma, J., and Davis, P.B. Functional dissection of the R domain of CFTR. *FEBS Letters*, 445:63-68, 1999
 92. Zerhusen, B., Zhao J., Xie, J., Davis, P.B. and Ma, J. A single conductance pore for chloride ion formed by two CFTR molecules. *J. Biol. Chem.* 274:7627-7630, 1999
 93. Davis P.B. The Gender Gap in CF Survival. *J. Gender-Specific Medicine* 2:47-52, 1999.
 94. Eckman, E., Mallender, W.D., Silski, C.L., Schreiber, J., Davis, P.B. and Ferkol, T.W. In vitro transport of active alpha1-antitrypsin to the apical surface of epithelia by targeting the polymeric immunoglobulin receptor. *Am. J. Respir. Cell Mol. Biol.* 21:246-252, 1999
 95. Van Heeckeren, A.M., Tscheikuna J, Walenga R.W., Konstan M.W., Davis P.B., Erokwu B., Haxhiu, M.A., Ferkol, T.W. Effect of *Pseudomonas* infection on weight loss, lung mechanics, and cytokines in mice, *Am. J. Resp. Crit. Care Med.* 161:271-279, 2000.

96. Ferkol, T.W., Eckman, E., Swaidani, S., Silski, C. and Davis P. Transport of bifunctional proteins across respiratory epithelial cells via the polymeric immunoglobulin receptor. *Am J Resp Crit Care Med.*, 161:944-951, 2000
97. Xie, J., Zhao, J., Davis, P.B., Ma, J. Conformation, independent of charge, in the R domain affects CFTR channel openings. *Biophysical J.* 78:1293-1305, 2000.
98. Davis, P.B. and Kercksmar, C.M. Growth in children with chronic lung disease (editorial) *New Engl J Med*, 342: 887-888, 2000
99. Kube, D., Sontich, C.U., Fletcher D Davis, P.B. Proinflammatory cytokine responses to *Pseudomonas aeruginosa* infection in human airway epithelial cell lines *Am J. Physiol.Lung Cell Mol Physiol.* 280:L493-L502, 2001
100. Rajan, S., Cacalano, G., Bryan, R., Ratner, A. Sontich, C.U., Davis, P.B. and Prince, A. *Pseudomonas aeruginosa* induction of apoptosis in respiratory epithelial cells. Analysis of the effects of cystic fibrosis transmembrane conductance regulation dysfunction and bacterial virulence factors. *Am J Resp Cell Mol Biol* 23:304-312,2000
101. Kube, D, Adams, L., Perez, A., and Davis, P.B. Terminal sialylation is altered in airway cells with impaired CFTR-mediated chloride transport. *Am J Physiol Lung Cell Mol Physiol* 280: L482-L492, 2001.
102. Gupta, S., Eastman, J., Silski, C., Ferkol, T., and Davis, P.B. Single chain Fv: a ligand in receptor-mediated gene therapy. *Gene Therapy* 8:586-92, 2001.
103. Schluchter MD, Konstan MW, Davis PB Jointly modeling the relationship between survival and pulmonary function in cystic fibrosis patients. *Stat. Med.* 21:1271-87, 2002
104. Ziady, A.G. Kelley, T. Milliken E, Ferkol T., Davis, P.B. Functional evidence of CFTR gene transfer in nasal epithelium of CF mice following apical application of SEC receptor targeted DNA complexes, *Mol. Therapy* 5: 413-419, 2002
105. Xie J., Adams L.M. Zhou J, Gerken T.A., Davis P.B., Ma J. A short segment of the R domain of CFTR contains channel inhibitory and stimulatory activities that are separable by sequence modification. *J Biol Chem*, 277: 23019-27, 2002
106. Ferkol, T. , Cohn L., Phillips T, Smith A. and Davis P.B. Targeted delivery of antiprotease to the epithelial surface of human tracheal xenografts. *Am J Resp Crit Care Med*, 167:1374-9, 2003
107. Konstan, MW, Krenicky JE, Feronti MR, Kirchner, HL, Hilliard KA, Davis PB and Hoppel CL Effect of Ibuprofen on Neutrophil Migration in Vivo in Cystic Fibrosis and Healthy Subjects *J. Pharmacology and Experimental Therapeutics*, 306(3):1086-91, 2003.
108. Davis, P.B. and Ziady, A.G. Non-viral methods of gene transfer to airway epithelium. *Gene Therapy and Regulation* 2:77-90, 2003
109. Chmiel JF, Davis PB. State of the Art: Why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? *Respir Res.* 2003 Aug 27;4(1):8
110. Ziady, A.G., Davis, P.B., and Konstan, M.W. Novel non-viral gene transfer therapy for cystic fibrosis *Expert Opinion on Biological Therapy* 3:449-458, 2003
111. Ziady, AG, Gedeon, CR. Miller, T, Quan, W. Payne JM, Hyatt SL, Fink TL, Muhammed O, Oette S, Kowalczyk, T. Pasumarthy M, Moen, RC, Cooper MC, and Davis, P.B. Transfection of Airway Epithelium by Stable PEGylated Poly-L-lysine DNA Nanoparticles In Vivo, *Mol Ther.* 8(6):936-47, 2003.
112. Gupta, S., Xie, J. Ma, J., and Davis, P.B. R domain: a site at which CFTR dimerization might be favored, *Am J Resp Cell Mol Biol*, 30(2):242-8, 2004. (Epub Aug 21, 2003)

113. Ziady AG, Gideon CR, Muhammad O, Stillwell V, Oette SM, Fink TL, Quan W, Kowalczyk TH, Hyatt SL, Peischl A, Seng JE, Moen RC, Cooper MJ, and Davis PB. Minimal Toxicity of Stabilized compacted DNA nanoparticles in the murine lung. *Mol Ther.* 8(6):948-56, 2003.
114. Van Heeckeren A, Scaria, A. Schluchter M, Ferkol TW Wadsworth S, and Davis, PB Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung improves survival in a model of chronic *Pseudomonas aeruginosa* lung infection, in press, *Am J. Physiol: Lung Cell and Mol Biol.* 286(4):L717-26, 2004.(Epub Sept 26, 2003)
115. Perez A and Davis PB Gene profile changes after *Pseudomonas aeruginosa* exposure in immortalized airway epithelial cells *J Struct Funct Genomics.* 2004;5(3):179-94.
116. Van Heeckeren A, Schluchter M, Xue L, Freedman S, Alvarez J, St.George J And Davis PB Nutritional effects on host response to chronic lung infections with mucoid *P. aeruginosa* in wild type and cystic fibrosis mice, in press, *Infection and Immunity* 72:1479-1486, 2004
117. Ziady AG, Kim J, Colla J, and Davis PB Defining strategies to extend duration of gene expression from targeted compacted DNA vectors. In press, *Gene Therapy* (epub)
118. Davis PB, Schluchter M, and Konstan MW Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis. *Pediatr Pulmonol.* 2004 Sep;38(3):204-9.
119. van Heeckeren AM Schluchter, MD Davis, PB Role of *Cftr* Genotype in the Response to Chronic *Pseudomonas aeruginosa* Lung Infection in Mice in press, *Am J. Physiology:Lung Cell and Molecular Physiology* (epub)
120. Davis PB, Drumm ML Some like it hot - curcumin and CFTR , in press, *Trends in Molecular Medicine*

Submitted Manuscripts

1. Kube, D., Fletcher, D. and Davis, P.B. Causes of increased inflammatory responses in CF airway epithelial cell lines.
2. Gupta S , Heacock M, Silski CL, Perez A, Davis PB Antibodies to the Polymeric Immunoglobulin Receptor with Different Binding and Trafficking Patterns
3. Konstan, MW, Davis, PB, Wagener, JS, Hilliard, KA, Stern, RC, Milgram, LJH Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady, AG Moen RC, and Cooper MJ Compacted DNA Nanoparticles Administered to the Nasal Mucosa of Cystic Fibrosis Subjects are Safe and Demonstrate Partial to Complete CFTR Reconstitution, in revision, *Human Gene Therapy*

Book Chapters

1. Davis, P.B. Cystic fibrosis in adults. In: *Textbook of Cystic Fibrosis.* John Lloyd-Still (ed.). John Wright PSG, Inc., pp. 351-370, 1983.
2. Davis, P.B. Cystic fibrosis factors. In: *Textbook of Cystic Fibrosis.* John Lloyd-Still (ed.). John Wright PSG, Inc., pp. 71-82, 1983.
3. Davis, P.B. Cystic fibrosis in adults. In: *Cystic Fibrosis.* Lynn M. Taussig (ed.). Brian C. Decker, New York, pp. 408-433, 1984.
4. Davis, P.B. Guest Editor, *Seminars in Respiratory Medicine*, Vol. 6, No. 4, 1985.
5. Davis, P.B. Functional consequences of regulatory dysfunction in cystic fibrosis. In: *Proceedings of the International Conference on the Cellular and Molecular Basis of Cystic Fibrosis*, P.M. Quinton and G. Mastella (eds.), San Francisco University Press, pp. 362-368, 1987.

6. Davis, P.B. Autonomic function in patients with airway obstruction. In: *The Airways: Neural Regulation in Health and Disease*. M.A. Kaliner and P. Barnes (eds.). Marcel Dekker, pp 87-118, 1988.
7. Davis, P.B. Cystic fibrosis. In: *Textbook of Internal Medicine*, W.N. Kelley (ed.), pp. 1899-1902, 1988. 2nd edition, 1991.
8. Davis, P.B. Airway responsiveness and atopy in cystic fibrosis. In: *Airways Responsiveness and Allergy in the Development of Chronic Lung Disease*. S. Weiss and D. Sparrow (eds.). Raven Press, pp. 293-313, 1989.
9. Davis, P.B. Cystic fibrosis: a major cause of obstructive airways disease in the young. In: *Chronic Obstructive Lung Disease*. N.S. Cherniack (ed.). W.B. Saunders Co., 1990, pp. 297-306.
10. Martin, R. and Davis, P.B. Relationship of neonatal and childhood lung disease to adult COPD. In: *Chronic Obstructive Lung Disease*. N.S. Cherniack (ed.). W.B. Saunders Co., 1990, pp. 286-294.
11. Davis, P.B., Kercksmar, C.M. Neural control of the airways. In: *The Physiologic Basis of Pediatric Pulmonology*. V. Chernick and R. Mellins (eds.), 1990, pp. 203-222.
12. Davis PB. Pathophysiology of the lung disease in cystic fibrosis. In: *Cystic Fibrosis: Lung Biology in Health and Disease Series*, Vol. 64. C. Lenfant, Exec. Ed. Marcel Dekker, Inc., New York, 1993, pp. 193-218.
13. Cotton CU and Davis PB. The pancreas in cystic fibrosis. In: *Cystic Fibrosis: Lung Biology in Health and Disease Series*, Vol. 64. C. Lenfant, Exec. Ed. Marcel Dekker, Inc., New York, 1993, pp. 161-192.
14. Ferkol, T.F. and Davis, P.B. Bronchiectasis and bronchiolitis obliterans. In: *Textbook of Pediatric Pulmonary Medicine*. Lynn M. Taussig (ed.). Mosby, Inc. St. Louis, MO, 1998, pp 784-794.
15. Davis, P.B. Special considerations in adults with cystic fibrosis. In: *The Hospitalized Patient with Cystic Fibrosis*. R.C. Stern and D. Orenstein, Editors. Marcel Dekker, New York 1997 pp. 319-336.
16. Davis, P.B. Pathophysiology of the cystic fibrosis lung disease In: *Cystic Fibrosis in Adults* J. Yankaskas, M.R. Knowles, Eds. Little, Brown, & Co. 1998, pp.45-68.
17. Infeld, M.D. and Davis, P.B. Cystic fibrosis and Bronchiectasis In: *Stein's Textbook of Medicine*, Mosby, St. Louis, MO, 1998, pp. 479-486.
18. Ma, J. and Davis, P.B. CFTR: What do we know? What don't we know? *Clinics in Chest Medicine*, 19:459-473, 1998
19. Davis, P. Applying the Center Concept: progressive benefits from the Network, in *Cystic Fibrosis in the 20th Century: people, events, and progress* C. F. Doershuk, Ed. AM Publishing Ltd., Cleveland OH, pp. 138-148 2001
20. Davis, P. Patient Care and Research, in *Cystic Fibrosis in the 20th Century: people, events, and progress* C. F. Doershuk, Ed. AM Publishing Ltd., Cleveland OH, pp. 403-405, 2001
21. Ziady, A.G. and Davis, P.B. Methods for the preparation of Receptor -Directed Molecular Conjugates for Gene Transfer In: *Gene Therapy Protocols*, J.Morgan, Ed. Humana Press Inc. *Methods Mol Med* 71:25-48, 2002.
22. Hilliard, J., Konstan, M.W., and Davis, P.B. Inflammatory Mediators in CF Patients In: *Cystic Fibrosis Methods*, W. Skach, ed. Humana Press Inc Totowa NJ, *Methods Mol Med* 70: 409-432, 2002
23. Davis, P.B. Cystic Fibrosis in Pediatrics in Review, R. Haggerty, Ed. Vol 22, pp. 257-264, 2001
24. Ziady, A.G. and Davis, P.B. Molecular conjugates. In *Vector Targeting for Therapeutic Gene Delivery* D. T. Curiel and J.T. Douglas, eds. John Wiley and Sons, Inc. pp 63-87, 2002

25. Davis, P.B. and Konstan, M. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. In *Advanced Drug Delivery Reviews*, Boucher R. and Hopkins S. Eds,(11):1395-408, 2002.
26. Davis, P.B. Cystic fibrosis lung disease in *Kendig's Pediatric Lung Disease 2004*

Books

1. Davis, P.B., Editor. *Cystic Fibrosis in Lung Biology in Health and Disease Series*. C. Lenfant, Series Editor. Marcel Dekker, New York, 1993.

Other Publications

1. Davis, P.B. and Smith, H.C. Similar effect of normal and cystic fibrosis serum on L-³H-fucose incorporation in fibroblasts. *IRCS Med. Sci.* 5:353, 1977.
2. Davis, P.B. Plasma factors do not account for the leukocyte beta adrenergic defect in cystic fibrosis. *IRCS Med. Sci.* 8:413, 1980.
3. Davis, P.B. "Diagnosis of Cystic Fibrosis in Adults." Slide-tape program produced by American Thoracic Society, 1982.
4. Davis, P.B. and Hubbard, V.S. GAP Conference Report on Heterozygote Detection and Prenatal Diagnosis of Cystic Fibrosis. March, 1982. Published by Cystic Fibrosis Foundation, Rockville, Maryland, 1982.
5. Davis, P.B. The clinical characteristics of the adult patient with cystic fibrosis. *Internal Medicine for the Specialist* 6:79-92, 1985.
6. Davis, P.B. Letter to the Editor: Alpha-adrenergic receptors on circulating cells. *J. Allergy Clin. Immunol.* 77: 769, 1986.
7. Davis, P.B. Letter to the Editor: Bronchiectasis and oligospermia. *Thorax*, 1985.
8. Davis, P.B. Cystic fibrosis: New perceptions, new strategies. *Hosp. Prac.* 27(11):79-118, 1992.

U.S. Patents

Serpin-Enzyme Complex Receptor Mediated Gene Transfer. Number 5,972,901 (October 1999) and 6,200,801 (March 2001).

The Delivery of Nucleic Acids to Cells. Number 5, 972,900 October, 1999

Fusion proteins for lung therapeutics. Number 6,072,041 (6/2000)

Bifunctional Molecules for Delivery for Therapeutics Number 6,261,787 July 17, 2001.

Fusion Proteins for Protein Delivery, US Patent Number 6,287,817 September 2001

Q4N2NEG2 enhances CFTR activity -6,770,739 August 2004

Invited Lectures and Conferences Outside Home Institution

October 1979	Speaker Canadian Cystic Fibrosis Association Retreat, Vancouver, B.C.
May 1980, 1981	Sunrise Seminars: "The Adult with Cystic Fibrosis". American Thoracic Society Meeting. 1980, Washington, DC; 1981, Detroit, MI
June 1980	Visiting Professor, University of North Carolina at Chapel Hill, Chapel Hill, NC
May 1980	Sunrise Seminar: "Tissue Culture in Cystic Fibrosis". 8th International Congress on Cystic Fibrosis, Toronto, Canada
October 1980	Visiting Professor, University of Arizona Center for the Health Sciences, Tucson, AZ
March 1981	Speaker, Cystic Fibrosis Foundation GAP Conference on "Biology of Mucins", Tempe AZ
November 1981	Second Annual Vivian Tappan Memorial Lecture. Yale University School of Medicine, New Haven, CT
February 1982	Visiting Professor, Hospital for Sick Children, Toronto, Ontario, Canada
March 1982	Visiting Professor, University of Wisconsin, Madison Center for Health Sciences, Madison, WI
March 1982	Panelist, GAP Conference on "Heterozygote Detection and Prenatal Diagnosis of Cystic Fibrosis" NY
September 1982	Participant, NIH/NIAMDK conference on Tissue Banking for Cystic Fibrosis Research, Bethesda MD
January 1983	Visiting Professor, Pulmonary Division, University of Michigan School of Medicine, Ann Arbor, MI
March 1983	Chairman, Cystic Fibrosis Foundation GAP Conference on "Pulmonary Infection in Cystic Fibrosis", Sandpiper Bay, FL
March 1984	Chairman, Cystic Fibrosis Foundation GAP Conference on "Endogenous Regulation in Cystic Fibrosis", Sandpiper Bay, FL
April 1984	First Richard C. Talamo Memorial Lecture: Massachusetts General Hospital, Harvard Medical School, Boston, MA
April 1984	Fourth Kit Taylor Memorial Lecture University of Rochester School of Medicine, Rochester, NY
May 1984	Third Annual Dorothy Wieselberg Seminar Speaker Montreal Chest Hospital Centre, McGill University, Montreal, Quebec
July 1984	Participant, NIH/NICHD Conference on Women in Clinical Research, Bethesda, MD
February 1985	Visiting Professor, Pulmonary Division, University of Iowa School of Medicine, Iowa City, Iowa
March 1985	Speaker, NHLBI Conference "Frontiers in Basic Sciences that Relate to Heart, Lung Blood Disease - Cystic Fibrosis", Bethesda, MD
March 1985	Speaker, Cystic Fibrosis Foundation GAP Conference "Signal Transduction and Intracellular Communication". Sandpiper Bay, FL
May 1985	Speaker, American Thoracic Society Symposium on Cystic Fibrosis, Anaheim, CA
July 1985	Seminar Speaker, NIH Seminar Series. Cystic Fibrosis, Bethesda, MD
February 1986	Speaker, Conference on Neural Regulation of the Airways in Health and Disease. Cancun, Mexico
February 1986	Speaker, GAP Conference on Cystic Fibrosis. Sandpiper Bay, FL
May 1986	Speaker, NIDR Conference on Salivary Gland Dysfunction. Bethesda, MD
September 1986	Speaker: NIH Workshop "Clinical-Behavioral Aspects of Cystic Fibrosis: Directions for Future Research". Bethesda, MD
September 1986	Symposium Speaker, Royal College of Physicians and Surgeons Toronto, Canada
February 1987	Speaker, Cystic Fibrosis Foundation GAP Conference, "Ion Channel Regulation in CF" Howey-in-the-Hills, Florida
March 1987	Participant, NHLBI Workshop "Infectious Injury to the Developing Lung". Bethesda, MD
May 1987	Session Chairman and Speaker, "Airway Cells and Secretions", American Thoracic Society meeting, New Orleans, LA
June 1987	Session Chairman and Speaker, International Symposium on the CF Basic Defect, Verona, Italy
October 1987	Visiting Professor, Pulmonary Division, Boston University School of Medicine, Boston, MA
October 1987	Panelist, Cell Culture for Cystic Fibrosis Research. North American Cystic Fibrosis Conference, Toronto, Canada
June 1988	Participant, GAP Conference on Inflammation in the Lung in CF, GAP Conference on Regulation of Ion Transport in CF, Williamsburg, VA
November 1988	Speaker, Conference on Gene Therapy for CF, Bethesda, MD
March 1989	Participant, Conference on G proteins, Bethesda, MD
May 1989	Plenary Session Chairman, AFCR/ASCI/AAP Meeting, Washington, D.C.

September 1989	Speaker, Conference on the CF Gene, Toronto, Ontario, Canada
March 1990	Speaker, UCLA Symposium "Airways Inflammation" Tamarron, Co
March 1990	Panelist, NIH Conference on CF Heterozygote Screening, Bethesda, MD
May 1990	Plenary Session Chairman, AFCE/ASCI/AAP Meeting, Washington, D.C., Presidential Address, AFCE
June 1990	Speaker, GAP Conference "The CF Gene Nine Months Later"
October 1990	Symposium Speaker and Chairman, International Cystic Fibrosis Meeting, Crystal City, VA
May 1991	Visiting Professor, University of Washington, Seattle
June 1991	Speaker, GAP Conference on Cell and Molecular Biology of Cystic Fibrosis, Williamsburg, VA
July 1991	Participant, Gordon Conference in Molecular Genetics, Newport, RI
October 1991	Symposium Speaker, International Cystic Fibrosis Meeting, Dallax, TX
November 1991	Speaker, Conference on Gene Therapy, Fairfax, VA
February 1992	Speaker, NHLBI Conference on Women's Lung Health, Bethesda, MD
May 1992	Session Chairman, Pulmonology, Society for Pediatric Research, Baltimore, MD
June 1992	Speaker, GAP Conference on Progress in CF, Williamsburg, VA
October 1992	Workshop Chairman, N. American CF Meeting, Washington, D.C.
October 1992	Director, Mini-Course, N. American CF Meeting, Washington, D.C.
1993, 1994	
December 1992	Speaker, Conference on Evaluation of Drugs for Cystic Fibrosis, sponsored by FDA/CFF, Washington, D.C.
January 1993	Speaker, Conference on CF Gene Therapy, Washington, D.C.
May 1993	Symposium Speaker, Molecular Biology of Cystic Fibrosis, SUNY Buffalo
June 1993	Speaker, GAP Conference on Molecular and Cellular Biology of CF, Williamsburg, VA
October 1993	Visiting Professor, U. of Chicago School of Medicine
April 1994	Visiting speaker, NHLBI Intramural Research
June 1994	Speaker, joint CFF-FDA Conference on Gene Therapy in CF, Williamsburg VA
September 1994	Speaker, Cold Spring Harbor Meeting on Gene Therapy
October 1994	Plenary Speaker, North American Cystic Fibrosis Conference, Orlando FL
October 1994	Speaker, Pediatric Travel Club, Cleveland OH
January 1995	Visiting Professor, University of California, San Diego
June 1995	Speaker, Williamsburg CF Conference on Gene Therapy
September 1995	Speaker, NIH Conference on the Genetics of Asthma, NHLBI, Bethesda, MD
November 1995	Visiting Professor, Department of Pediatrics, University of Cincinnati
January 1996	Speaker, Emma Thaler Symposium in honor of E. Rossi, Munich, Germany
April 1996	Visiting Professor, Department of Pediatrics, University of California, San Diego
April 1996	ASPET Experimental Biology '96 Symposium speaker "New Approaches to the Therapy of Cystic Fibrosis"
May 1996	Visiting Professor, University of California at San Francisco, Cystic Fibrosis Gene Therapy Center
May 1996	Symposium Speaker, ATS Meeting, New Orleans, LA
June 1996	Session chair, Williamsburg meeting on CF Gene Therapy; Participant, Williamsburg meeting on Cell and Molecular Biology of CF
September 1996	Speaker, Page-Wood Symposium, Cleveland OH
October 1996	Speaker, Cambridge Symposium on Molecular Genetic Approaches to the Treatment of Genetic Disease, Lake Tahoe, NV
October 1996	Visiting professor, University of Michigan Department of Pediatrics
December 1996	Visiting professor, Ohio State University Gene Therapy Center
December 1996	Speaker, Ohio Physiologic Society Annual Meeting "Horizons in Physiology" Cleveland OH
June 1997	Participant, Williamsburg CF Meetings
September 1997	Participant, CF Foundation Conference on TOBI therapy
October 1997	Invited speaker, Conference on Gene Therapy, Paris, France
October 1997	Chair, North American Cystic Fibrosis Conference, Nashville TN Plenary Speaker Director, Mini-course on CF for the Nonclinician
December 1997	Visiting Professor, University of Chicago
January 1998	Visiting Professor, Hospital for Sick Children, Toronto, Ontario, Canada
February 1998	Visiting Professor, University of Pennsylvania, Gene Therapy Center
May 1998	Poster Symposium Chair, APS/SPR meetings, New Orleans LA
May 1998	Invited speaker, Society for Human Gene Therapy Meeting, Seattle, WA

June 1998	Invited speaker, Williamsburg CF Meetings
September 1998	Session chair, Cold Spring Harbor Gene Therapy Meeting
October 1998	Plenary speaker, North American CF Conference, Montreal, Quebec. Symposium speaker Workshop Chair
November 1998	Enrichment speaker, Stanford University CF Research Program
December 1998	Visiting Professor, University of Texas Southwestern Dallas, TX
May 1999	Session Chair, APS/SPR meetings, San Francisco, CA
June 1999	Speaker and Session Chair, Williamsburg CF meetings
June 1999	Invited speaker, annual meeting of the American Society for Gene Therapy
October 1999	Symposium chair, North American CF Conference, Seattle WA
November 1999	Participant and speaker, CFF meeting on modifier gene identification, Bethesda MD
February 2000	Session chair and speaker, CFF meeting on Inflammation in the CF Lung, Fairfax, VA
May 2000	Session chair and speaker, Williamsburg CF meetings
June 2000	Session chair, American Society for Gene Therapy Meetings, Denver CO
November 2000	Symposium chair and speaker, North American CF Conference, Baltimore MD
March 2001	Chair and speaker - Workshop on proteomics for Cystic Fibrosis, Bethesda MD
April 2001	Visiting speaker - Stanford University Cystic Fibrosis Research Program.
May 2001	Invited speaker, Pharmaceutical Biotechnology Symposium , University of Michigan, Ann Arbor, MI
August 2001	Visiting scientist, Murdoch Research Institute, Royal Childrens Hospital, Melbourne AU "Gene Therapy for CF"
August 2001	Plenary Speaker, and speaker in lay and medical topics symposia, Australian Cystic Fibrosis Conference, Brisbane, Australia
September 2001	Keynote speaker, German Cystic Fibrosis Association, Dusseldorf, Germany
September 2001	Invited speaker -University of North Carolina at Chapel Hill, Cystic Fibrosis Center
October 2001	Discussant, Conference on Gene Therapy, Rome Italy
October 2001	Symposium Chair, North American CF Conference, Orlando, FL
March 2002	Speaker, Denver Children's Hospital, Denver CO
April 2002	Speaker, International Meeting on Stem Cell Therapy, Paris, France
June 2002	Session chair, New Technologies, Williamsburg CF Conference, Williamsburg, VA
July 2002	Keynote speaker, Respiratory Workshop, Rotorua, New Zealand "Inflammation in CF" Visiting professor, Starship Hospital, Auckland, New Zealand "Impact of the Discovery of the CF Gene" Visiting professor, Christchurch Hospital, Christchurch, New Zealand "Gene Therapy for CF"
August 2002	Keynote speaker MetroHealth Medical Center Research Day "Gene Therapy for CF: hope or hype?"
October 2002	Visiting scientist, Centacor Corp. Philadelphia, PA "Inflammation in CF"
November 2002	Visiting professor, Dept of Physiology NEOUCOM, Rootstown OH "Inflammation in the CF lung"
December 2002	Grand Rounds speaker, Dept of Pediatrics, Cleveland Clinic "Update on CF"
February 2003	Keynote speaker, National Cystic Fibrosis Meeting, Killarney, Ireland
April 2003	Grand Rounds speaker, University of Michigan, "Gene Therapy for Cystic Fibrosis: Hope or Hype?"
April 2003	Visiting Professor University of California at Davis "Gene Therapy for Cystic Fibrosis: Hope or Hype?"
June 2003	Invited speaker, American Society for Gene Therapy, Workshop on Gene Transfer to the Respiratory Tract
June 2003	Invited speaker Cystic Fibrosis Foundation Williamsburg CF Conference, Report on a Gene Therapy Clinical Trial, Epithelial responses to Pseudomonas
June 2003	Session chair and moderator, NIH Conference BECON 2003 "Catalyzing Team Science"
September 2003	Invited speaker, NIH Symposium on CFTR "The Dimer Hypothesis for CFTR function"
October 2003	Symposium Chair and speaker, North American CF Conference, Anaheim CA "Evaluation of outcome measures for gene therapy trials" Workshop speaker Speaker at Psychosocial group meeting "Gender effects in CF"
October 2003	Invited speaker, Department of Physiology, University of Cincinnati, "Inflammation in CF Lungs"
November 2003	Invited speaker, Department of Physiology, Robert Wood Johnson School of Medicine,

February 2004 "Inflammation in the CF lung"
Speaker BIO CEO Meeting "Cystic fibrosis: brief summary" New York, NY
April 2004 Invited speaker, CF Foundation Therapeutics Development Network Meeting, "Animal Models
for evaluating CF therapeutics"
June 2004 Invited symposium speaker, American Society for Gene Therapy, Minneapolis MN
Meet the professor luncheon, ASGT, Minneapolis, MN
June 2004 Session chair and speaker, Williamsburg CF Conference, Lipid mediators in CF.
October 2004 Plenary Speaker, North American Cystic Fibrosis Conference St. Louis, MO
October 2004 Invited speaker, Nanomedicine Summit, Cleveland Clinic Foundation.

Home Institution and Local Presentations Not Listed

Grants Awarded: Past:

Cystic Fibrosis Foundation Young Investigator Award
 "Autonomic Nervous System Dysfunction in Patients with Pulmonary Diseases"
 3/1/80 - 2/28/82; \$57,766, P.I.: P.B. Davis

American Lung Association of Tennessee
 "Alpha Adrenergic and Cholinergic Abnormalities in Asthma"
 7/1/80 - 6/30/81; \$11,200, P.I.: P.B. Davis

Veterans Administration Regional Advisory Group
 "Autonomic Nervous System Function in Pulmonary Diseases"
 7/1/81 - 9/30/82; \$33,978, P.I.: P.B. Davis

March of Dimes Birth Defects Foundation: Basil O'Connor New Investigator Award
 "Membrane Abnormalities in Cystic Fibrosis"
 9/1/81 - 6/30/84; \$64,537, P.I.: P.B. Davis

Veterans Administration Career Development Award: Research Associate
 "Autonomic Nervous System Function in Obstructive Pulmonary Diseases"
 10/1/82 - 1/20/85 Full salary plus \$5000/yr research funds. P.I.: P.B. Davis

Veterans Administration Central Office Merit Review
 "Autonomic Nervous System Function in Obstructive Pulmonary Disease"
 1/1/82 - 9/30/85; \$105,291, P.I.: P.B. Davis (renewed and funded 10/1/85 - 9/30/90, relinquished).

Cystic Fibrosis Foundation (National) Contract
 "Ibuprofen Pharmacokinetics in Patients with Cystic Fibrosis"
 3/1/86-6/30/87; \$48,000, P.I.: P.B. Davis (no % stated)

Fannie E. Rippel Foundation, Award of \$165,500 to equip CF cell culture facility. W.T. Speck, M.D. Principal Investigator, P.B. Davis, Program Director

NIA AG 04391 Teaching Nursing Home Award, Case Western Reserve, P.I. A.B. Ford. \$1,779,645 (TDC). Project #4 "Autonomic and Airway Reactivity in the Aged"
 10/83- 9/88; \$343,571 (TDC), P.I.: P.B. Davis, (20%)

Parker B. Francis Foundation Fellowship to James Stark, M.D., Ph.D.
 7/1/86-6/30/89; TDC \$81,000. Program Director P.B. Davis

Cystic Fibrosis Foundation (Rainbow Chapter)
 "CF Core Center: Mediator Assay Core"
 3/1/86-12/31/89; ADC \$30,000, P.I.: P.B. Davis, (no % stated)

Cystic Fibrosis Foundation (National): Research Development Program Component III Center 6/1/86-5/31/91, \$1,375,000 for construction of new laboratory space.
 P.I.: William T. Speck, M.D. - Program Director P.B. Davis

Cystic Fibrosis Foundation (Rainbow Chapter)
 "CF Core Center: Epithelial Cell Culture Core"
 3/1/86-12/31/90; ADC \$30,000, P.I.: P.B. Davis (no %)
 Cystic Fibrosis Foundation (Rainbow Chapter) Clinical Scholar in CF Fellowship
 7/1/87-6/30/91; ADC \$30,000, P.B. Davis, Program Director

Cystic Fibrosis Foundation (National)
 "Neutrophil Mediated Damage to Human Airway Epithelial Cells"
 1/1/89-12/31/90; ADC \$65,000, P.I.: P.B. Davis, 5%

National Institutes of Health/National Heart, Lung, and Blood Institute: HL-28386
 "Membrane Abnormalities in Cystic Fibrosis"

2/1/82-3/31/85 - TDC \$215,771; 4/1/85-3/31/91 - TDC\$434,504, P.I.: P.B. Davis, (25%)

Cystic Fibrosis Foundation (National)

“Antibodies to CFTR”

4/1/90-3/31/92; TDC \$50,000, P.I.: P.B. Davis.

Cystic Fibrosis Foundation (National)

“Four Year Clinical Trial of Ibuprofen in Patients with Cystic Fibrosis”

P.I.: P.B. Davis, 1988-1990; P.I. switched to Michael Konstan, 1991-1993 with P. Davis co-investigator

ADC \$180,000; TDC \$900,000. (25%)

Fannie E. Rippel Foundation, \$150,000 for laboratory equipment, P.I.: P. Davis, 8/92.

National Institutes of Health/National Institute of Diabetes, Digestive, and Kidney Disease RO1-DK-43999

“Targeting Genes to Cells Relevant for Cystic Fibrosis”

4/1/91-3/31/96; ADC \$115,000 - TDC \$700,000, P.I.: P.B. Davis (10%).

National Institutes of Health/National Heart, Lung, and Blood Institute P50 HL-37117 SCOR Grant “Chronic Diseases of the Airways”, E.R. McFadden, P.I.;

Interactions of Neutrophils with Airway Epithelial Cells In Vitro, P.B. Davis, Project Director

12/1/91-11/30/96, ADC \$120,000 - TDC \$680,000 (20% effort).

Cystic Fibrosis Foundation Molecular Engineering of Protein Constructs for Gene Delivery in CF

1/1/95-12/31/96. ADC \$50,000 P.I. P.B. Davis

National Institutes of Health/National Heart, Lung, and Blood Institute RO1-HL-49003

“Cell and Animal Models of Impaired Chloride Transport”

7/1/92-3/31/97; ADC \$210,000 - TDC \$900,000 P.I.: P.B. Davis (15% effort) (renewal returned to accept P50 grant).

National Institutes of Health/National Heart, Lung and Blood Institute SCOR P50 HL51060

“Therapeutic Approaches to the CF Lung Disease”

9/30/93-9/29/98, ADC \$415,000 - TDC \$2,200,000 PI: P.B. Davis (20%)

National Institutes of Health/National Institute of Diabetes, Digestive and Kidney Diseases R01 DK49138 Receptor-Mediated Gene Transfer into Airway Cells.

10/1/94-9/30/99 ADC \$125,000, P.I.: P.B. Davis 15%

Cystic Fibrosis Foundation. Engineering a non-immunogenic vector for Gene Therapy of CF

12/1/96-11/30/99 ADC \$125,000, P.I. P.B. Davis (no % stated)

Cystic Fibrosis Foundation. Etiology of airway infections in CF.

6/9/97-5/31/00 ADC \$100,000. P.I. P.B. Davis. (No % stated)

Cystic Fibrosis Foundation (National) Leroy Matthews Physician-Scientist Training Program (Institutional Award) 3 M.D. positions

7/1/89-6/30/01 6 years' support for each, average ADC \$100,000 P.I.: P.B. Davis (no % stated)

Cystic Fibrosis Foundation. Activating mutant forms of CFTR. 5/1/00-4/30/02 ADC \$60,000 P.B. Davis, P.I. (5%)

National Institutes of Health/ NIDDK R01 DK52981 “Targeting the Sec-Receptor for Gene Therapy”

7/1/98 to 6/30/03 ADC \$151,000, P.B. Davis, P.I. (20%)

Copernicus Therapeutics Sponsored Research Agreement “Studies in receptor-mediated gene transfer”

1/1/02-12/31/02 \$100,000 P.B. Davis, PI (no % stated)

National Institutes of Health/National Heart Lung and Blood Institute SCOR P50 HL60293 “Inflammation in the CF Lung”

9/30/98 to 9/30/03 ADC \$860,000 P.B. Davis, P.I. (25%) (P.I. on Project 1 and Administrative Core)

Cystic Fibrosis Foundation RFA on Inflammation: Inflammation in the CF Lung P.B. Davis, PI, ADC \$125,000 11/1/00-10/31/03

Cystic Fibrosis Therapeutics, Inc. New therapeutic targets for inflammation P.B. Davis, PI (15%) ADC \$125,000 4/1/01-3/31/04

Cystic Fibrosis Foundation Targeting the polymeric immunoglobulin receptor for CF therapeutics P. Davis PI. 4/1/02 to 3/31/04 \$64,800 per year, (5%)

Sponsorship of Career Development Awards (Past):

Scott Mader, M.D. NIH/NIA AG00387-01, Clinical Investigator Award, ADC \$60,000; TDC \$300,000/5 yrs. 8/1/87-7/31/92.

Michael Konstan, M.D. Harry Shwachman Clinical Investigator Award, National Cystic Fibrosis Foundation \$60,000/yr. 1988-1991.

Stephen E. Alpert, M.D., NIH/NHLBI KO8 HL-02430 Clinical Investigator Award; "Modulation of Arachidonic Acid Cascade in Airway Epithelium" 4/1/90-3/31/95; ADC \$60,000; TDC \$300,000/5 yrs.

Michael D. Infeld, M.D., NIH/NHLBI (K08) "Regulation of Airway Submucosal Gland Development" 4/1/93-3/31/97, ADC \$72,000, TDC \$360,000

Paul Smith, D.O. K08 HL03409 Physical stress increases smooth muscle contractility ADC \$75,000 7/1/97-6/30/02

Active Grants:

National Institutes of Health/National Institute of Diabetes, Digestive and Kidney Diseases P30-DK 27651 "Core Center: Cystic Fibrosis" 4/1/86-3/31/06; ADC \$750,000, TDC \$3,750,000, P.I.: P. B. Davis, (20%).

National Institutes of Health/National Heart, Lung, and Blood Institute T32-HL07415 "Pediatric Pulmonary Disease and Cystic Fibrosis Training Grant" 7/89-6/09, 2 predocs, 7 postdocs, average ADC \$300,000, P.I.: P.B. Davis (10%)

Cystic Fibrosis Foundation (National) RDP Program "CF Research Center" 4/1/91-6/30/05; ADC \$400,000 P.I.: P.B. Davis (no % stated).

National Institutes of Health R01DK 58318 Accessing the SEC receptor for cystic fibrosis gene therapy. P.B. Davis, P.I. (15%) \$235,000 ADC 9/1/00-7/30/09

NIH HL-68883 Murine Models to Identify CF Modifiers 10/01/01-09/29/06 Mitchell Drumm, P.I. ADC \$422,989 (P. Davis effort, 5%)

Cystic Fibrosis Foundation Evaluating toxicity from Gene Therapy 4/1/04 to 3/31/06 \$64,800 per year, (5%)

Cystic Fibrosis Foundation Targeting the Sec-Receptor for Gene Therapy P.B. Davis, PI ADC \$75,000 9/1/02-8/31/04

National Institutes of Health R21DK/EB002574-01 Polymeric immunoglobulin receptor targeting of airways P.B. Davis, PI ADC \$125,000 12/1/03-11/30/05. (5%)

Cystic Fibrosis Foundation "Inflammation in the CF lung" 8/1/03 to 12/31/04 \$50,000 per annum (5%)

Cystic Fibrosis Therapeutics Inc "Laser capture microdissection of airway epithelium for gene array studies" \$100,000/yr 3/1/04-2/28/06, 5%.

National Institutes of Health NHLBI HL73870 "Inflammation in the CF lung" P. Davis, P.I. \$250,000 per year (20%) 12/1/04-12/1/09 pending (10th percentile) September 15, 2004